CD19 — Global Competitive Landscape Report 2026 | EHA 2026June 24, 2026 CD19 is a foundational target for B-cell malignancies, with a wealth of data presented at…
CD19 Competitive Landscape: CAR-T, Bispecifics, and Autoimmune Expansion | ASCO 2026June 9, 2026 CD19 remained the dominant target for B-cell malignancy therapies in ASCO 2026 hematology presentations. Tafasitamab’s…
CD19 — Global Competitive Landscape Report 2026May 11, 2026 This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates…
